个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

The History and Development of HER2 Inhibitors

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Xia Xiaohui[1] * ; Gong Chen[1] * ; Zhang Yinan[2] ; Xiong Huihua[1] ;
单位： [1]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. [2]School of Chemical Science and Engineering, Tongji University, Shanghai 200092, China.
出处：
DOI： 10.3390/ph16101450
ISSN：

关键词： HER2 inhibitors cancer antibodies tyrosine kinase inhibitors antibody-drug conjugates

摘要：
HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mainly include monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs). This article reviews the development of HER2 inhibitors for various tumors over the past 20 years.

语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 3 区 医学
小类 | 3 区 药学 3 区 药物化学
最新[2025]版：
大类 | 3 区 医学
小类 | 2 区 药学 3 区 药物化学
JCR分区：
出版当年[2021]版：
Q1 PHARMACOLOGY & PHARMACY Q2 CHEMISTRY, MEDICINAL
最新[2024]版：
Q1 CHEMISTRY, MEDICINAL Q1 PHARMACOLOGY & PHARMACY

影响因子： 最新[2024版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者单位： [1]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Xia Xiaohui,Gong Chen,Zhang Yinan,et al.The History and Development of HER2 Inhibitors[J].PHARMACEUTICALS.2023,16(10):doi:10.3390/ph16101450.
APA：
Xia Xiaohui,Gong Chen,Zhang Yinan&Xiong Huihua.(2023).The History and Development of HER2 Inhibitors.PHARMACEUTICALS,16,(10)
MLA：
Xia Xiaohui,et al."The History and Development of HER2 Inhibitors".PHARMACEUTICALS 16..10(2023)

相关文献

[1]Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer [2]A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors [3]Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy [4]Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors [5]Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer [6]Retrospective Analysis of Chinese Chronic Myeloid Leukemia Patients Who Have Stopped Tyrosine Kinase Inhibitors [7]Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer [8]Computational analysis of receptor tyrosine kinase inhibitors and cancer metabolism: implications for treatment and discovery of potential therapeutic signatures [9]Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study in China [10]Defining the sensitivity landscape of EGFR variants to tyrosine kinase inhibitors

资源点击量：899 今日访问量：1 总访问量：637 更新日期：2025-12-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）